Edition:
United Kingdom

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

3.02USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$3.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,312
52-wk High
$4.09
52-wk Low
$1.34

Latest Key Developments (Source: Significant Developments)

Sierra Oncology reports net loss $0.19 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Sierra Oncology Inc ::Sierra Oncology reports third quarter results.Qtrly ‍net loss per share, basic and diluted $0.19​.  Full Article

ProNAi licenses oncology drug targeting DNA damage response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
Tuesday, 27 Sep 2016 

ProNAi Therapeutics Inc : ProNAi will pay CRT Pioneer fund an upfront payment of us$7.0 million . Additional payments in aggregate amount of up to $319.5 million may become payable upon achievement of certain development,among others . ProNAi licenses oncology drug targeting DNA damage response Checkpoint kinase 1 (Chk1) from CRT Pioneer Fund, UK . PNT737 currently in phase 1 clinical trials at Royal Marsden, London, UK .Has obtained an exclusive license from CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737.  Full Article

ProNAi Therapeutics Q2 net loss of $12.9 mln
Friday, 12 Aug 2016 

ProNAi Therapeutics Inc : ProNAi Therapeutics reports second quarter 2016 results .Qtrly net loss of $12.9 million compared to a net loss of $15.2 million.  Full Article

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT